# Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

> **NCT06650501** · PHASE4 · RECRUITING · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 300 (estimated)

## Conditions studied

- Staphylococcus Aureus Endocarditis
- Staphylococcus Aureus Septicemia
- Staphylococcus Aureus Bacteremia
- Staphylococcus Aureus Bloodstream Infection
- S. Aureus Bacteremia
- S. Aureus Bloodstream Infection

## Interventions

- **DRUG:** Dabigatran
- **DRUG:** Apixaban
- **DRUG:** edoxaban
- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT06650501
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2030-01
- **Final completion:** 2030-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650501, "Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06650501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*